Advertisement
RayBiotech
RayBiotech

The Scientist

» pharmaceuticals

Most Recent

image: Drugging the Environment

Drugging the Environment

By | August 1, 2015

Humans have spiked ecosystems with a flood of active pharmaceuticals. The drugs are feminizing male fish, confusing birds, and worrying scientists.

1 Comment

image: Biotech Buys Autoimmune Firm for $7B

Biotech Buys Autoimmune Firm for $7B

By | July 16, 2015

Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.

0 Comments

image: FDA OKs Herpes Blood Test

FDA OKs Herpes Blood Test

By | July 6, 2015

The US Food and Drug Administration approves Theranos’s fingerstick test for herpes.

0 Comments

image: Organ-on-a-Chip Gets Big Pharma Boost

Organ-on-a-Chip Gets Big Pharma Boost

By | June 18, 2015

Johnson & Johnson agrees to use Emulate’s blood-clot device in three of its preclinical drug programs.

0 Comments

image: Endo to Pay $8 Billion for Par

Endo to Pay $8 Billion for Par

By | May 19, 2015

The deal would create one of the five biggest generic drugmakers in the U.S.

0 Comments

image: Drugmaker Teva Bids $40 Billion for Mylan

Drugmaker Teva Bids $40 Billion for Mylan

By | April 23, 2015

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

0 Comments

image: AbbVie Wins Bidding War for Cancer Drugmaker

AbbVie Wins Bidding War for Cancer Drugmaker

By | March 5, 2015

The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.

0 Comments

image: Shire Makes $5.2 Billion Buy

Shire Makes $5.2 Billion Buy

By | January 13, 2015

The Irish drugmaker moves on from its terminated sale to AbbVie to purchase New Jersey-based NPS Pharmaceuticals.

0 Comments

image: Spinoff Company to Develop Rare Disease Drugs

Spinoff Company to Develop Rare Disease Drugs

By | January 7, 2015

Maryland-based Vtesse will work with the US National Institutes of Health to advance treatments for Niemann-Pick Type C disease and other lysosomal storage disorders.

1 Comment

image: Merck Buys Cubist for $8.4B

Merck Buys Cubist for $8.4B

By | December 11, 2014

Hours after the pharmaceutical giant announced the acquisition, a federal judge invalidated key patents behind the antibiotic maker’s most lucrative product.

0 Comments

Advertisement

Popular Now

  1. Most Earth-like Planet Found
  2. AAAAA Is for Arrested Translation
  3. Four-legged Snake Fossil Found
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
Advertisement